Marcello Dominici

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Pascal Vranckx, Marco Valgimigli, Peter Jüni et al. · The Lancet · 2018 · 761 citations

Endovascular Technique, Cardiovascular Disease, Randomised Superiority Trial +8

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

Patrick W. Serruys, Bernard Chevalier, Dariusz Dudek et al. · The Lancet · 2014 · 556 citations · Full text

Percutaneous Coronary Intervention, Absorb Ii, Endovascular Technique +11

Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial

Patrick W. Serruys, Bernard Chevalier, Yohei Sotomi et al. · The Lancet · 2016 · 534 citations · Full text

Percutaneous Coronary Intervention, Absorb Ii, Everolimus-eluting Metallic Stent +10

Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting

Anna Franzone, Eugène McFadden, Sergio Leonardi et al. · Journal of the American College of Cardiology · 2019 · 145 citations

Percutaneous Coronary Intervention, Thrombosis, Cardiovascular Disease +10

Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial

Patrick W. Serruys, Kuniaki Takahashi, Ply Chichareon et al. · European Heart Journal · 2019 · 119 citations · Full text